Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasmanda Wu

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Endocrinology, Diabetes & Metabolism|November 22, 2021
Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world studySean D Sullivan, Nick Freemantle, Rishab A Gupta, et al.
Clinical Therapeutics|February 4, 2014
Assessment of dronedarone utilization using US claims databasesJasmanda Wu, Jane Thammakhoune, Wanju Dai, et al.
Pulmonary Therapy|July 16, 2024
Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation SuspensionJuzar Ali, Jasmanda Wu, Mariam Hassan, et al.
Advances in Therapy|July 19, 2020
Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World StudyJavier Escalada, Fabrice Bonnet, Jasmanda Wu, et al.
Pulmonary Circulation|November 10, 2025
Incremental Burden of Pulmonary Hypertension Among Patients With Interstitial Lung Disease in the Real-World SettingCharles D Burger, Jasmanda Wu, Gerald O'Brien, et al.
Psychiatric Services (Washington, D.C.)|August 23, 2012
Exposure to potentially dangerous drug-drug interactions involving antipsychoticsJeff Jianfei Guo, Jasmanda Wu, Christina M L Kelton, et al.
Respiratory Medicine|May 11, 2024
Association between bronchiectasis exacerbations and longitudinal changes in FEV<sub>1</sub> in patients from the US bronchiectasis and NTM research registryTimothy R Aksamit, Nicole C Lapinel, Radmila Choate, et al.
Diabetes, Obesity & Metabolism|July 3, 2019
Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3)Timothy S Bailey, Jasmanda Wu, Fang L Zhou, et al.
Diabetes, Obesity & Metabolism|May 31, 2019
Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world studySean D Sullivan, Charlie J Nicholls, Rishab A Gupta, et al.
Pulmonary Circulation|June 17, 2026
A Phase 2 Study of the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Hypertension Associated With Interstitial Lung DiseaseColin Church, Maria Molina-Molina, Miguel Arias-Guillén, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Endocrinology, Diabetes & Metabolism|November 22, 2021
Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world studySean D Sullivan, Nick Freemantle, Rishab A Gupta, et al.
Clinical Therapeutics|February 4, 2014
Assessment of dronedarone utilization using US claims databasesJasmanda Wu, Jane Thammakhoune, Wanju Dai, et al.
Pulmonary Therapy|July 16, 2024
Qualitative Interviews Exploring Adverse Event Mitigation Strategies in Adults Receiving Amikacin Liposome Inhalation SuspensionJuzar Ali, Jasmanda Wu, Mariam Hassan, et al.
Advances in Therapy|July 19, 2020
Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World StudyJavier Escalada, Fabrice Bonnet, Jasmanda Wu, et al.
Pulmonary Circulation|November 10, 2025
Incremental Burden of Pulmonary Hypertension Among Patients With Interstitial Lung Disease in the Real-World SettingCharles D Burger, Jasmanda Wu, Gerald O'Brien, et al.
Psychiatric Services (Washington, D.C.)|August 23, 2012
Exposure to potentially dangerous drug-drug interactions involving antipsychoticsJeff Jianfei Guo, Jasmanda Wu, Christina M L Kelton, et al.
Respiratory Medicine|May 11, 2024
Association between bronchiectasis exacerbations and longitudinal changes in FEV<sub>1</sub> in patients from the US bronchiectasis and NTM research registryTimothy R Aksamit, Nicole C Lapinel, Radmila Choate, et al.
Diabetes, Obesity & Metabolism|July 3, 2019
Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3)Timothy S Bailey, Jasmanda Wu, Fang L Zhou, et al.
Diabetes, Obesity & Metabolism|May 31, 2019
Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world studySean D Sullivan, Charlie J Nicholls, Rishab A Gupta, et al.
Pulmonary Circulation|June 17, 2026
A Phase 2 Study of the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Hypertension Associated With Interstitial Lung DiseaseColin Church, Maria Molina-Molina, Miguel Arias-Guillén, et al.
Pageof 2